Trials / Unknown
UnknownNCT04275583
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3602 | This is a kind of proteasome inhibitor. |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
- First posted
- 2020-02-19
- Last updated
- 2020-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04275583. Inclusion in this directory is not an endorsement.